Making Gains in HFpEF: An Appraisal of Where We Are Now

Published: 27 June 2022

  • Views:

    Views Icon 2526
  • Likes:

    Heart Icon 0


Full programme


In this symposium, part of Heart Failure Online 2022, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with an left ventricular ejection fraction >40%.


In addition to hearing about the data which led to changes in the recent ACC guidelines, the faculty also explore the impact of clinical inertia and the remaining challenges in HFpEF management.

This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. It is not intended for US or UK based healthcare professionals.

Key Learning Objectives

Upon participation in this programme physicians should be able to:

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Series overview

Part 1

Patient Case – Typical Patient With HFpEF

Part 2

SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell

Part 3

Early Initiation of Foundational Therapy in HF: Why the Urgency?

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

University of Manitoba, Canada

Dr Shelley Zieroth is at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.

Dr Zieroth attended medical school at the University of Manitoba, where she went on to train in internal medicine and cardiology. She completed her postdoctoral clinical fellowship, specializing in advanced heart failure and cardiac transplant, at Toronto General Hospital. Dr Zieroth has lectured internationally on the subject of heart failure.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile
Javed Butler

Javed Butler

Professor of Medicine

Dr Javed Butler is President, Baylor Scott and White Research Institute, Dallas, TX and Professor of Medicine, University of Mississippi, Jackson, MS, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He has authored more than 900 peer-reviewed publications.


View full profile
Carolyn Lam

Carolyn Lam

Professor and Senior Consultant

Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.

View full profile